ReviewRSC advances2023
The recent development of nanozymes for targeting antibacterial, anticancer and antioxidant applications.
Review in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Multifunctional Vitamin BAntioxidants (Basel, Switzerland) · 2026Article
- Engineering Catalytic Nanozymes for Antimicrobial Food Systems: Structure-Activity Relationships, Safe-by-Design Principles, and Industrial Translation.Nanomaterials (Basel, Switzerland) · 2026Review
- A Dual-Functional Biohybrid Nanorobot to Synergistically Eradicate Biofilm and Degrade Antibiotic Resistance Genes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Beyond antibiotics: engineered metal nanozymes for resistance-evading antibacterial therapy.Journal of nanobiotechnology · 2026Review
- Biomedical applications and perspectives of two-dimensional porphyrin-based MOFs.Frontiers in pharmacology · 2026Review
- Iron oxide nanoparticles: biosynthesis, peroxidase-like activity, and biosafety.Applied microbiology and biotechnology · 2025Review
- Mesoporous Silica-Encapsulated Cerium Oxide Nanozymes and Quercetin for Synergistic ROS-Modulated Downregulation of Inflammatory Cytokines.International journal of nanomedicine · 2025Article
- The potential use of nanozymes as an antibacterial agents in oral infection, periodontitis, and peri-implantitis.Journal of nanobiotechnology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nowadays, nanozymes have not only been used as biosensors in the detection field, but also their application prospects in disease treatment have been explored. Numerous nanomaterials have similar catalytic activities such as peroxidase, oxidase, catalase and superoxide dismutase, and they can be used for antibacterial, anticancer and antioxidant therapy. Although there have been many studies on the application of nanozymes in the therapeutic field, the current nanozyme-based systems often lack targeting and ignore the harm to the surrounding normal tissues. Although promising, the biosafety of nanomaterials has always been the concern of researchers. To improve the treatment effect and reduce toxic and side effects, precision treatment has become the key. At present, a few studies have modified targeted molecules on nanozymes to achieve precise targeting through specific interaction with surface overexpression factors of bacteria or cells. Combined with the catalysis of nanozymes, the targeted treatment of diseases can be achieved. This review summarizes the current research of nanozyme systems in targeted antibacterial, anticancer and antioxidant applications. At the same time, the challenges and development prospects of nanozyme-based targeted therapy system are summarized. It is expected that this work will provide new ideas and new directions for the precise treatment of nanozymes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.